cdc travel immunizations thailand

Travel Vaccines and Advice for Thailand

Thailand is a popular destination with its tropical climate, food, culture and beaches.

Thai is the official language of Thailand. But, other smaller languages spoken in rural areas. The primary religion of Thailand is Buddhism and is prevalent in many aspects of culture throughout Thailand. Islam is also practiced in Southern provinces.

Bangkok, Thailand’s capital city, is also the largest city in the country. Bangkok is highly populated with congested streets, modern buildings and temples. It is most known for its nightlife.

Thailand’s other major cities include Ayutthaya, Chiang Mai, and Chiang Rai.

On This Page: Do I Need Vaccines for Thailand? Other Ways to Stay Healthy in Thailand Do I Need a Visa or Passport for Thailand? What Is the Climate Like in Thailand? How Safe Is Thailand? Temples in Thailand What Should I Take to Thailand? U.S. Embassy in Thailand

Do I Need Vaccines for Thailand?

Yes, some vaccines are recommended or required for Thailand. The CDC and WHO recommend the following vaccinations for Thailand: typhoid , cholera , hepatitis A , polio , yellow fever , Japanese encephalitis , chikungunya , rabies , hepatitis B , influenza , COVID-19 , pneumonia , meningitis , chickenpox , shingles , Tdap (tetanus, diphtheria and pertussis) and measles, mumps and rubella (MMR) .

See the bullets below to learn more about some of these key immunizations:

• Typhoid – Food & Water – Shot lasts 2 years. Oral vaccine lasts 5 years, must be able to swallow pills. Oral doses must be kept in refrigerator.
• Cholera – Food & Water – Cholera is rare, but present in Thailand. Vaccination is recommended for travelers at increased risk or visiting areas with active transmission.
• Hepatitis A – Food & Water – Recommended for most travelers.
• Polio – Food & Water – Due to an increase in cases globally, an additional adult booster is recommended for most travelers to any destination.
• Yellow Fever – Mosquito – Required if traveling from a country with risk of yellow fever transmission.
• Japanese Encephalitis – Mosquito – Recommended depending on itinerary and activities. Recommended for extended travel, recurrent travelers and travel to rural areas. Present throughout country, especially northern regions. Most cases from May to October.
• Chikungunya – Mosquito – Thailand is a higher risk region. Vaccination is recommended.
• Rabies – Saliva of Infected Animals – High risk country. Vaccine recommended for long-term travelers and those who may come in contact with animals.
• Hepatitis B – Blood & Body Fluids – Recommended for travelers to most regions.
• Influenza – Airborne – Vaccine components change annually.
• COVID-19 – Airborne – Recommended for travel to all regions, both foreign and domestic.
• Pneumonia – Airborne – Two vaccines given separately. All 65+ or immunocompromised should receive both.
• Meningitis – Direct Contact & Airborne – Given to anyone unvaccinated or at an increased risk, especially students.
• Chickenpox – Direct Contact & Airborne – Given to those unvaccinated that did not have chickenpox.
• Shingles – Direct Contact – Vaccine can still be given if you have had shingles.
• Polio – Food & Water – Considered a routine vaccination for most travel itineraries. Single adult booster recommended.
• TDAP (Tetanus, Diphtheria & Pertussis) – Wounds & Airborne – Only one adult booster of pertussis required.
• Measles Mumps Rubella (MMR) – Various Vectors – Given to anyone unvaccinated and/or born after 1957. One time adult booster recommended.

See the table below for more information:

Specific Vaccine Information

• Typhoid – Typhoid, caused by Salmonella Typhi, spreads via contaminated food and water, especially in areas with poor sanitation. Protect yourself by practicing good hygiene and safe food habits. Vaccination can significantly reduce the risk of typhoid infection, especially when traveling to endemic areas.
• Hepatitis A – Be sure to protect yourself from hepatitis A, a contagious liver infection caused by HAV, through vaccination. The virus spreads through contaminated food, water, and close contact. Along with vaccination, maintaining proper hygiene and avoiding undercooked shellfish are essential for prevention.
• Japanese Encephalitis – Japanese encephalitis is a mosquito-spread viral disease that affects the central nervous system. Prevention is achieved through protective attire and vaccination.
• Chikungunya – Chikungunya, a mosquito-borne virus, can be prevented by avoiding mosquito bites and reducing breeding sites. The chikungunya vaccine provides the best protection.
• Rabies – Rabies is a deadly viral illness transmitted mainly through animal bites. Vaccination is pivotal, with pre-exposure and post-exposure options available to protect against this potentially fatal disease.
• Hepatitis B – The hepatitis B virus leads to liver infection through contact with infected fluids. The most effective safeguard is the hepatitis B vaccine, administered in a series of shots that stimulate the body to produce antibodies, providing long-term immunity. It is crucial for infants and those at an increased risk of exposure.
• Measles, Mumps, Rubella (MMR) – Measles, mumps, and rubella are viral infections that can spread through close contact and respiratory droplets. Vaccination is the most effective way to halt their transmission. The MMR vaccine, given in two doses, strengthens immunity, reducing the chances of contracting and spreading these diseases.

Malaria in Thailand

Malaria in Thailand is primarily found in border provinces near Myanmar, Cambodia, Laos and Malaysia. Rare cases occur in other regions. Chloroquine resistance is present in the country. Atovaquone, doxycycline, mefloquine and tafenoquine are suggested as antimalarials if traveling to the region. Consult with a travel health specialist on which antimalarial will best fit your needs.

Japanese encephalitis vaccines are mandatory for those living in rural areas, hiking or camping. Those that plan to stay longer than a month should consider getting vaccinated.

Various mosquito-borne diseases are present in Thailand. Malaria poses a threat to travelers to some regions of the country. Make sure you are protected with antimalarials.

Medical treatment is adequate and common in urban areas. Healthcare is also available in rural areas, though the health care providers may not speak English.

To find out more about these vaccines, see our vaccinations page . Ready to travel safely? Book your appointment either call or start booking online now .

Other Ways to Stay Healthy in Thailand

Prevent bug bites in thailand.

Safeguard against bug bites by dressing appropriately and using EPA-registered repellents with DEET, picaridin, or OLE. If bitten, cleanse the area, refrain from scratching, and mitigate discomfort with OTC treatments. Seek medical aid for serious reactions.

Food and Water Safety in Thailand

When traveling, ensure food safety by adhering to CDC recommendations, which include eating fully cooked foods, avoiding raw seafood, and selecting reputable dining places. Safely drink bottled beverages, avoiding ice in uncertain water sources, and consume alcohol in moderation. Prevent travelers’ diarrhea through hand hygiene and avoiding street food in unsanitary areas.

Altitude Sickness in Thailand

Altitude sickness, characterized by symptoms like headache and nausea stemming from oxygen deprivation at high elevations, can be prevented through gradual ascent, hydration, and medication like acetazolamide. Should AMS symptoms arise, immediate descent to lower altitudes, rest and seek medical attention.

Infections To Be Aware of in Thailand

• Avian/Bird Flu – Avian flu, also known as bird flu, is a contagious virus that affects birds and can spread to humans. Preventing it involves vaccination of poultry, strict biosecurity on farms, safe handling and cooking of poultry, surveillance for outbreaks, and raising public awareness.
• Dengue – Dengue fever is a mosquito-borne illness with symptoms ranging from mild to severe, including high fever and pain. The CDC emphasizes prevention through avoiding mosquito bites by using repellents and removing standing water. Treatment focuses on symptom relief and hydration, avoiding certain pain relievers that can worsen bleeding risks.
• Leishmaniasis – Leishmaniasis is transmitted by sand flies’ bites. To prevent its spread, individuals should use insect repellents, wear long-sleeved clothing and limit outdoor activities during sand fly activity periods. Eliminating breeding sites and early diagnosis are crucial for effective prevention.
• Zika – Zika, a mosquito-borne virus, can cause mild to severe symptoms and poses significant risks during pregnancy. Prevention strategies include using insect repellent, safe sex practices, and avoiding travel to affected areas.

Do I Need a Visa or Passport for Thailand?

U.S. citizens staying in Thailand for 30 days or less do not need a visa. But, their passport must be valid for at least six months from the date of entry.

Sources: Embassy of Thailand and U.S. State Department

Always carry your passport and visa with you to avoid arrest in Thailand.

What Is the Climate Like in Thailand?

Thailand is a country with a tropical climate that is hot and humid throughout the year. The temperature ranges from 25 to 35 degrees Celsius during the day. The weather can be different depending on where you are in Thailand. Here are some popular tourist destinations:

• Bangkok : Bangkok is hot and humid all year round. It rains a lot, especially between May and October.
• Phuket : Phuket is a tropical place. It can rain a lot from May to October. The temperature is usually between 75 and 90 degrees.
• Chiang Mai : Chiang Mai has a tropical climate with three different seasons: cool, hot, and rainy. The cool season runs from November to February, the hot season from March to May, and the rainy season from June to October.
• Pattaya : Pattaya is hot and humid all year round. It rains a lot, especially between May and October.
• Koh Samui : Koh Samui is an island that has two different seasons: dry and rainy. The dry season runs from December to April, and the rainy season from May to November.

Remember that weather can change, so always check the forecast before you travel.

How Safe Is Thailand?

In the past few years, there have been periodic terrorist attacks at popular tourist attractions in Thailand,. This remains a high-concern today. There is an ongoing risk of terrorist attacks in Thailand.

The National Council for Peace and Order (NCPO) has placed strict restrictions on media and have banned political gatherings. Tourists may be detained by the military for openly criticizing the NCPO.

Pick-pocketing is common in Thailand as is sexual violence in bars and isolated areas.

Do not use your passport as collateral. Many rental places are scams.

In Southern Thailand (Yala, Pattani, Narathiwat, and Songkhla), martial law is still prevalent. Tourists are cautioned against traveling to these areas.

Temples in Thailand

Avoid mosquitoes and other bugs, insect-borne disease are a threat throughout the world., keep the bugs away with passport health’s repellent options .

There are over 40,000 temples in Thailand, making them popular tourist attractions. These temples range in age and architecture and many are still in use today.

Wat Pho, located in Bangkok, is one of the most popular due to its size and attractions within. It is one of the largest complexes in the country, holding many buildings. Wat Pho houses the largest reclining Buddha and largest collection of Buddha images.

The site is also headquarters for the teaching and preservation of Thai medicine. There, tourists can find two massage schools and pavilions.

You must take off your shoes to enter and you purchase coins to put into bowls for good luck. All the money goes towards renovating and up-keeping the site.

What Should I Take to Thailand?

Thailand is a hot and humid country, it’s important to pack lightweight and comfortable clothing. You should bring comfortable shoes for walking, sun protection like sunscreen, hats, and sunglasses to avoid the strong sun rays. Mosquitoes are common in Thailand, so it’s important to bring insect repellent to avoid bites.

Thailand uses different types of electrical outlets, so it’s recommended to bring a universal adapter. It’s also recommended to pack any prescription medication and over-the-counter medications such as pain relievers, anti-diarrhea medication, and motion sickness medication.

Thailand is a cash-based society, so it’s important to bring cash and credit cards. If you plan to visit the beaches or go swimming, don’t forget to pack swimwear and a beach towel. When visiting temples or other religious sites, make sure to dress respectfully, covering your shoulders and knees, and avoid wearing revealing clothing in public places.

Don’t forget to bring your passport, visa (if required), travel insurance, and any other important travel documents.

U.S. Embassy in Thailand

All Americans visiting Tunisia should register online with the U.S. Department of State before departure. This will inform the office of your travel plans within the country and will allow them to reach out in the case of an emergency or evacuation.

Once in Thailand, the information for the U.S. Embassy is:

U.S. Embassy Bangkok 95 Wireless Road Bangkok 10330 Thailand Telephone: + (66) (2) 205-4049, 02-205-4049 (within Thailand) Emergency After-Hours Telephone: +(66) (2) 205-4000, 02-205-4000 (within Thailand) Fax: +(66) (2) 205-4103, 02-205-4103 (within Thailand) Email: [email protected]

If you have any questions about traveling to Thailand or are wondering what shots you may need for your trip, schedule an appointment with your local Passport Health travel medicine clinic. Call us at or book online now! and protect yourself today.

Customer Reviews

Passport health – travel vaccines for thailand.

• Records Requests
• Passport Health App
• Privacy Center
• Online Store

• Quick Links
• Make An Appointment
• Our Services
• Price Estimate
• Price Transparency
• Pay Your Bill
• Patient Experience
• Careers at UH

Schedule an appointment today

Thailand Travel Requirements & Vaccinations

Thailand is a country located in Southeast Asia on the Indochinese peninsula. Officially known as the Kingdom of Thailand, it was formerly known as Siam. Thai is the official language of Thailand with English being spoken in most of the larger cities and tourist destinations. Thailand is home to some of the most popular and luxurious resorts in Asia.

The terrain of Thailand varies greatly and ranges from mountainous regions in the north, to plateaus in the east and river valleys in much of the interior. Despite the geographical variations, most of Thailand experiences a tropical wet and dry (savanna) climate which is comprised of three distinct seasons:

• Summer or pre-monsoon season lasts from mid-February to mid-May and is characterized by warm, dry temperatures.
• Rainy or southwest monsoon season lasts from mid-May to mid-October and is defined by an abundance of rain.
• Winter or northeast monsoon season is mid-October through mid-February and comes with dry, mild weather conditions.

Thailand has a vast array of attractions and activities to offer visitors, including:

• Bangkok and the many historical, natural and cultural sights it has to offer
• Trekking and adventure travel in the forested mountain regions
• Archaeological sites, Buddhist temples and museums
• Clear blue/green shallow waters on sandy beaches along the coast
• A diverse wildlife system

Recommended Vaccinations for Thailand Travel

• Hepatitis A
• Japanese encephalitis

*Rabies vaccination is typically only recommended for very high risk travelers given that it is completely preventable if medical attention is received within 7 – 10 days of an animal bite.

Travelers may also be advised to ensure they have received the routine vaccinations listed below. Some adults may need to receive a booster for some of these diseases:

• Measles, mumps and rubella (MMR)
• Tdap (tetanus, diphtheria and pertussis)

Older adults or those with certain medical conditions may also want to ask about being vaccinated for shingles and/or pneumonia.

This information is not intended to replace the advice of a travel medicine professional. Not all of the vaccines listed here will be necessary for every individual.

Talk to the experts at UH Roe Green Center for Travel Medicine & Global Health to determine how each member of your family can obtain maximum protection against illness, disease and injury while traveling, based on age, health, medical history and travel itinerary.

Make an Appointment

To schedule a pre-travel consultation call, 216-844-8500 .

Please note: You must be physically located in Ohio for a virtual consultation

What Can You Do to Help?

Make a gift to support urgent patient care at University Hospitals.

You are using an outdated browser. Upgrade your browser today or install Google Chrome Frame to better experience this site.

• Section 2 - Interactions Between Travel Vaccines & Drugs
• Section 2 - Travelers’ Diarrhea

Yellow Fever Vaccine & Malaria Prevention Information, by Country

Cdc yellow book 2024.

Author(s): Mark Gershman, Rhett Stoney (Yellow Fever) Holly Biggs, Kathrine Tan (Malaria)

The following pages present country-specific information on yellow fever (YF) vaccine requirements and recommendations, and malaria transmission information and prevention recommendations. Country-specific maps are included to aid in interpreting the information. The information in this chapter was accurate at the time of publication; however, it is subject to change at any time due to changes in disease transmission or, in the case of YF, changing entry requirements for travelers. Updated information reflecting changes since publication can be found in the online version of this book and on the Centers for Disease Control and Prevention (CDC) Travelers’ Health website. Recommendations for prevention of other travel-associated illnesses can also be found on the CDC Travelers’ Health website .

Yellow Fever Vaccine

Entry requirements.

Entry requirements for proof of YF vaccination under the International Health Regulations (IHR) differ from CDC’s YF vaccination recommendations. Under the IHR, countries are permitted to establish YF vaccine entry requirements to prevent the importation and transmission of YF virus within their boundaries. Certain countries require proof of vaccination from travelers arriving from all countries ( Table 5-25 ); some countries require proof of vaccination only for travelers above a certain age coming from countries with risk for YF virus transmission. The World Health Organization (WHO) defines areas with risk for YF virus transmission as countries or areas where YF virus activity has been reported currently or in the past, and where vectors and animal reservoirs exist.

Unless issued a medical waiver by a yellow fever vaccine provider, travelers must comply with entry requirements for proof of vaccination against YF.

WHO publishes a list of YF vaccine country entry requirements and recommendations for international travelers approximately annually. But because entry requirements are subject to change at any time, health care professionals and travelers should refer to the online version of this book and the CDC Travelers’ Health website for any updates before departure.

CDC Recommendations

CDC’s YF vaccine recommendations are guidance intended to protect travelers from acquiring YF virus infections during international travel. These recommendations are based on a classification system for destination-specific risk for YF virus transmission: endemic, transitional, low potential for exposure, and no risk ( Table 2-08 ). CDC recommends YF vaccination for travel to areas classified as having endemic or transitional risk (Maps 5-10 and 5-11 ). Because of changes in YF virus circulation, however, recommendations can change; therefore, before departure, travelers and clinicians should check CDC’s destination pages for up-to-date YF vaccine information.

Duration of Protection

In 2015, the US Advisory Committee on Immunization Practices published a recommendation that 1 dose of YF vaccine provides long-lasting protection and is adequate for most travelers. The recommendation also identifies specific groups of travelers who should receive additional doses, and others for whom additional doses should be considered (see Sec. 5, Part 2, Ch. 26, Yellow Fever ). In July 2016, WHO officially amended the IHR to stipulate that a completed International Certificate of Vaccination or Prophylaxis is valid for the lifetime of the vaccinee, and YF vaccine booster doses are not necessary. Moreover, countries cannot require proof of revaccination (booster) against YF as a condition of entry, even if the traveler’s last vaccination was >10 years ago.

Ultimately, when deciding whether to vaccinate travelers, clinicians should take into account destination-specific risks for YF virus infection, and individual risk factors (e.g., age, immune status) for serious YF vaccine–associated adverse events, in the context of the entry requirements. See Sec. 5, Part 2, Ch. 26, Yellow Fever , for a full discussion of YF disease and vaccination guidance.

Table 2-08 Yellow fever (YF) vaccine recommendation categories 1

Malaria prevention.

The following recommendations to protect travelers from malaria were developed using the best available data from multiple sources. Countries are not required to submit malaria surveillance data to CDC. On an ongoing basis, CDC actively solicits data from multiple sources, including WHO (main and regional offices); national malaria control programs; international organizations; CDC overseas offices; US military; academic, research, and aid organizations; and the published scientific literature. The reliability and accuracy of those data are also assessed.

If the information is available, trends in malaria incidence and other data are considered in the context of malaria control activities within a given country or other mitigating factors (e.g., natural disasters, wars, the coronavirus disease 2019 pandemic) that can affect the ability to control malaria or accurately count and report it. Factors such as the volume of travel to that country and the number of acquired cases reported in the US surveillance system are also examined. In developing its recommendations, CDC considers areas within countries where malaria transmission occurs, substantial occurrences of antimalarial drug resistance, the proportions of species present, and the available malaria prophylaxis options.

Clinicians should use these recommendations in conjunction with an individual risk assessment and consider not only the destination but also the detailed itinerary, including specific cities, types of accommodations, season, and style of travel, as well as special health conditions (e.g., pregnancy). Several medications are available for malaria prophylaxis. When deciding which drug to use, consider the itinerary and length of trip, travelers’ previous adverse reactions to antimalarials, drug allergies, medical history, and drug costs. For a thorough discussion of malaria and guidance for prophylaxis, see Sec. 5, Part 3, Ch. 16, Malaria .

Entry requirements : Required for travelers ≥9 months old arriving from countries with risk for YF virus transmission; this includes >12-hour airport transits or layovers in countries with risk for YF virus transmission. 1

CDC recommendations : Not recommended

• Primarily the provinces that border Burma, Cambodia (few cases in Buri Ram Province), and Malaysia (few cases in Satun Province) Also, the provinces of Phitsanulok and Ubon Ratchathani (bordering Laos), and Surat Thani (especially in the rural forest and forest-fringe areas of these provinces)
• Rare to few cases in other parts of Thailand, including the cities of Bangkok (the capital), Chiang Mai, and Chiang Rai, or on the islands of Koh Pha Ngan, Koh Samui, or Phuket
• No malaria transmission on the islands of Krabi Province (Ko Lanta, Koh Phi, Koh Yao Noi, Koh Yao Yai) or in Pattaya City
• Chloroquine and mefloquine
• P. vivax (80%)
• P. falciparum (<20%)
• P. knowlesi 6 , P. malariae , and P. ovale (rare)
• Provinces that border Burma, Cambodia (except Buri Ram Province), and Malaysia (except Satun Province); the provinces of Phitsanulok, Ubon Ratchathani, and Surat Thani: Atovaquone-proguanil, doxycycline, tafenoquine 3
• All other areas with malaria transmission (including the provinces of Buri Ram and Satun): No chemoprophylaxis recommended (insect bite precautions and mosquito avoidance only) 4

Related Maps

Map 2-16 malaria prevention in thailand, other vaccines to consider.

See Health Information for Travelers to Thailand .

View Larger

1 Current as of November 2022. This is an update of the 2010 map created by the Informal WHO Working Group on the Geographic Risk of Yellow Fever.

2 Refers to Plasmodium falciparum malaria, unless otherwise noted.

3 Tafenoquine can cause potentially life-threatening hemolysis in people with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. Rule out G6PD deficiency with a quantitative laboratory test before prescribing tafenoquine to patients.

4 Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide-treated mosquito net, and wearing protective clothing (e.g., long pants and socks, long-sleeve shirt). For additional details on insect bite precautions, see Sec. 4, Ch. 6, Mosquitoes, Ticks & Other Arthropods.

5 Primaquine can cause potentially life-threatening hemolysis in people with G6PD deficiency. Rule out G6PD deficiency with a quantitative laboratory test before prescribing primaquine to patients.

6 P. knowlesi is a malaria species with a simian (macaque) host. Human cases have been reported from most countries in Southwest Asia and are associated with activities in forest or forest-fringe areas. P. knowlesi has no known resistance to antimalarials.

Yellow Fever Maps

2 In 2017, the Centers for Disease Control and Prevention (CDC) expanded its YF vaccination recommendations for travelers going to Brazil because of a large YF outbreak in multiple states in that country. Please refer to the CDC  Travelers’ Health website for more information and updated recommendations.

3 YF vaccination is generally not recommended for travel to areas where the potential for YF virus exposure is low. Vaccination might be considered, however, for a small subset of travelers going to these areas who are at increased risk for exposure to YF virus due to prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Factors to consider when deciding whether to vaccinate a traveler include destination-specific and travel-associated risks for YF virus infection; individual, underlying risk factors for having a serious YF vaccine–associated adverse event; and destination entry requirements.

The following authors contributed to the previous version of this chapter: Mark D. Gershman, Emily S. Jentes, Rhett J. Stoney (Yellow Fever) Kathrine R. Tan, Paul M. Arguin (Malaria)

File Formats Help:

• Adobe PDF file
• Microsoft PowerPoint file
• Microsoft Word file
• Microsoft Excel file
• Audio/Video file
• Apple Quicktime file
• RealPlayer file
• Zip Archive file

A .gov website belongs to an official government organization in the United States.

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

• About the Global Health Center
• Global Health Strategic Framework
• Our Organization
• Divisions and Offices
• Our Success Stories
• Partnerships
• Where We Work
• Global Health Observances
• Regional Offices
• Our Newsletter

Related Topics:

• View All Home
• Global Immunization
• Global HIV and TB
• Global Health Protection
• Global Health Equity

CDC in Thailand

At a glance.

For over 40 years, CDC has collaborated with public health institutions in Thailand to address major public health challenges in the country, throughout Southeast Asia, and beyond. CDC supports Thailand in global health security, including providing technical and financial support to partners on surveillance in animal and human health, laboratory and workforce development and emergency response.

CDC has worked with Thailand's Ministry of Public Health (MOPH) since 1980. CDC, MOPH, and partner organizations work together to address the following public health areas:

• Public health workforce development.
• Public health laboratory readiness.
• Emergency operations centers (EOCs) and rapid response teams.
• Treatment and prevention of HIV and sexually transmitted infections.
• Migration health.
• Influenza surveillance, prevention and migration measures.
• Pandemic preparedness.

Global health security

Strategic focus.

CDC supports Thailand in achieving the goals outlined in the Global Health Security Agenda (GHSA) and implementing the International Health Regulations . Thailand is a member country of GHSA, a permanent member of the GHSA Steering Group. Thailand also served as the Chair of the GHSA Steering Group in 2021.

CDC's global health security work focuses on strengthening the country's public health systems across the following core areas:

Surveillance systems

CDC funding helps support various surveillance system strengthening efforts in Thailand, including:

• Wastewater surveillance in quarantine settings to validate the early detection of SARS-CoV-2.
• Surveillance of COVID-19 in patients presenting with febrile illness and post COVID-19 conditions in Nakhon Phanom and Tak Provinces.
• Improving early warning and response for dengue infection.
• Laboratory-based surveillance of antimicrobial resistant organisms in four Thai Regional Medical Science Centers.
• Sentinel surveillance for influenza among those with severe acute respiratory infections and influenza-like illnesses.

Laboratory systems strengthening

CDC funding aims to improve capabilities to detect, confirm, and identify pathogens of public health importance for global health security. This work includes training, surge capacity testing during public health emergencies, and research.

Workforce development

CDC supports training scientists through the Field Epidemiology Training Program (FETP) , established in Thailand in 1980. FETP participants gain the skills to collect, analyze, and interpret data and contribute to evidence-based decisions during outbreak responses. The program consists of three levels of training: frontline, intermediate, and advanced.

CDC and the Thai FETP also established the FETP-Emerging Infectious Diseases track. Through this track, residents work with CDC staff to gain experience in emerging infectious diseases. Residents and graduates have played central roles in Thailand’s successful response to numerous infectious disease outbreaks. They have also been integral to staffing Thailand’s Public Health EOC.

CDC also supports a newly established Southeast Asia Regional Global Laboratory Leadership Program. This training program is designed to foster and mentor current and emerging leaders to build, strengthen, and sustain national laboratory systems.

Emergency response

CDC works to strengthen capacity of Thailand's emergency preparedness response operations. This work aims to improve emergency management in Thailand, and across neighboring Cambodia, Laos, and Malaysia. CDC supported activities include:

• Establishment of the Thai public health EOC.
• Strengthening Thailand’s emergency preparedness and response system both at the national and sub-national levels.
• Enhanced surge capacity of the Thai MOPH rapid response teams to support investigation and response to outbreaks, including COVID-19.

Key achievements

• With CDC support, Thailand completed Joint External Evaluations in 2017 and 2022, a National Action Plan for Health Security in 2019, and chaired the GHSA Steering Committee in 2021.
• More than 1,100 public health workers have graduated from the Thai FETP since 1980.
• Development of a national electronic COVID-19 vaccine registry and certificate system that is used to verify vaccination status for international travel.
• From 2020 - 2023, CDC's laboratory in Thailand performed more than 10,000 COVID-19 diagnostic tests in support of Thai government partners, the International Rescue Committee, and the U.S. Embassy community.
• The establishment and strengthening of Thailand’s Coordinating Unit for One Health.

Through the U.S. Presidential Emergency Plan for AIDS Relief ( PEPFAR ), CDC partners with Thailand to build a robust national HIV response. The PEPFAR South and Southeast Region Program includes a diverse group of 5 countries: Burma (Myanmar), Cambodia , Laos , Nepal and Thailand. The PEPFAR regional coordination unit is based in Bangkok. This office provides advice in planning, budgeting, program implementation, results monitoring, and reporting.

CDC's work focuses on 14 Thai provinces with high HIV burden. Activities include efforts to:

• Strengthen disease surveillance systems, laboratory capacity, case-finding strategies, and safe delivery of medicine.
• Promote pre-exposure prophylaxis (PrEP) use.
• Implement programs to reduce HIV-related stigma and discrimination.
• Promote continuous quality improvement along the HIV continuum of care.
• Conduct and support research on injectable long-acting PrEP and new prevention and treatment strategies like non-daily PrEP and antibiotics for sexually transmitted infections.

Global Leader in HIV Prevention‎‎

In 2022, in coordination with CDC and other partners, Thailand developed the Community-Based-Organization (CBO) certification standard. To ensure domestic financing for HIV services, Thailand advocated for CBOs to be reimbursed by the National Health Services Office.

In 2021, CDC and partners in Thailand and other countries researched a novel PrEP drug. They included men and transgender women who have sex with men in the trial. The results from the trial demonstrated that injectable and long-acting drug is safe and effective. This resulted in the registration of the drug by the U.S. Food and Drug Administration (FDA) in 2021. The drug was also approved by Thailand FDA in 2023. This led to the issuance of new treatment recommendations and policies by the CDC and others.

In 2019, CDC supported expansion of the national PrEP and index partner testing programs. This resulted in a three-fold increase in Thai government funding for PrEP. It also increased government PrEP service outlets, and expansion of provinces providing index testing services.

In 2016, with CDC support, Thailand received World Health Organization (WHO) certification for elimination of mother-to-child transmission of HIV and syphilis. Thailand was the first Asian country to receive this certification.

In 2013, MOPH and CDC conducted the world's first trial demonstrating that PrEP reduces HIV spread among people who inject drugs.

Antimicrobial resistance (AMR)

CDC provides technical assistance to support Thailand's national strategic plan to prevent, detect, and respond to AMR. CDC activities include:

• Assessing the capacity of health facilities in Bangkok to detect and respond to AMR.
• Strengthening national and sub-national AMR laboratory networks.
• Building capacity to identify novel mechanisms of resistance.
• Providing specimens, strengthening quality of collected data, and supporting expansion of WHO's supported Enhanced Gonorrhea Antimicrobial Surveillance Programme.

CDC, MOPH, the Global Antibiotic Research and Development Partnership, and others, completed a groundbreaking, global study of a novel, first-in-class medication. Based on promising results, and awaiting regulatory approval, the drug, zoliflodacin, is poised to become the first antibiotic for treating gonorrhea. This would represent significant advancement in the fight against AMR infections.

Migration health

CDC’s global migration health experts address public health threats before they cross international borders. CDC experts help prevent the spread of disease among international travelers, immigrants, refugees, and other mobile populations in Southeast Asia. CDC provides technical support to Thai MOPH and Lao MOH on disease surveillance, emergency response and disease prevention at border crossings. Activities include:

• This system has been expanded to include influenza and meningococcal vaccination records for Hajj pilgrims.
• Support of disease detection and prevention at international points of entry in Laos and Thailand through training for officers, testing, and reporting systems.
• Development of migrant health volunteer networks in multiple provinces, training hundreds of migrant workers on disease prevention measures and administering surveys to understand perceptions and concerns in migrant communities.
• Partnership with the Thai Red Cross Society to support the development of an innovative biometric system to uniquely identify migrants or other persons without identification documents for access to healthcare services such as vaccinations.
• Development of multisectoral collaboration networks in 6 target border provinces across Thailand, building information exchange and preparation for future incident responses.
• Support for healthy US-bound refugee and immigrant movements via high-quality medical examinations, vaccinations, and treatments. This program detects and treats serious communicable diseases in refugees and immigrants before they relocate to the U.S., preventing further spread.

CDC supports Thailand to sustain robust influenza surveillance and develop effective seasonal influenza vaccination programs with full regulatory and delivery systems. These efforts increase local, regional, and global pandemic preparedness. CDC's primary objectives include:

• Providing epidemiologic and laboratory technical support for influenza detection, response, and prevention activities in Southeast Asia.
• Growing the evidence-base to inform policy decisions for influenza prevention and control programs, including influenza vaccination.
• Supporting pandemic preparedness in Thailand and partner countries.

CDC supports Thailand to sustain sentinel surveillance and sequencing of viruses to monitor circulating influenza and respiratory pathogens. The Thailand National Influenza Center is recognized as a regional leader in surveillance and laboratory training to neighboring countries.

Seasonal influenza viruses first identified in Thailand have been included in the seasonal influenza vaccines since 2015. This contribution helps protect people worldwide.

CDC supported the Thailand Government Pharmaceutical Organization on clinical trials of domestically produced seasonal influenza vaccine and COVID-19 vaccine. This work helps to strengthen Thai health security.

Related links

Global health.

CDC's Global Health Center works 24/7 to reduce illness and respond to health threats worldwide.

We’re sorry, this site is currently experiencing technical difficulties. Please try again in a few moments. Exception: request blocked

Security Alert May 17, 2024

Worldwide caution.

• Travel Advisories |
• Contact Us |
• MyTravelGov |

Find U.S. Embassies & Consulates

Travel.state.gov, congressional liaison, special issuance agency, u.s. passports, international travel, intercountry adoption, international parental child abduction, records and authentications, popular links, travel advisories, mytravelgov, stay connected, legal resources, legal information, info for u.s. law enforcement, replace or certify documents.

Share this page:

Thailand Travel Advisory

Travel advisory july 24, 2023, thailand - level 1: exercise normal precautions.

Reissued with obsolete COVID-19 page links removed.

Exercise normal precautions in Thailand. Some areas have increased risk.  Read the entire Travel Advisory.

Reconsider travel to:

• Yala, Pattani, Narathiwat, and Songkhla provinces due to  civil unrest associated with ongoing insurgent activities.

Read the  country information page  for additional information on travel to Thailand.

If you decide to travel to Thailand:

• Enroll in the  Smart Traveler Enrollment Program (STEP)  to receive Alerts and make it easier to locate you in an emergency.   
• Follow the Department of State on  Facebook  and  Twitter .   
• Review the  Country Security Report  for Thailand.
• Have evacuation plans that do not rely on U.S. government assistance.
• Visit the CDC page for the latest  Travel Health Information  related to your travel.
• Prepare a contingency plan for emergency situations. Review the  Traveler’s Checklist .

Yala, Pattani, Narathiwat, and Songkhla Provinces – Level 3: Reconsider Travel

Periodic violence directed mostly at Thai government interests by a domestic insurgency continues to affect security in the southernmost provinces of Yala, Pattani, Narathiwat, and Songkhla. In Songkhla, the insurgency is most active in the districts of Chana, Thepha, Nathawat, and Saba Yoi. U.S. citizens are at risk of death or injury due to the possibility of indiscriminate attacks in public places.

The U.S. government has limited ability to provide emergency services to U.S. citizens in these provinces as U.S government employees must obtain special authorization to travel to these provinces.

Visit our website for  Travel to High-Risk Areas .

Travel Advisory Levels

Assistance for u.s. citizens, thailand map, search for travel advisories, external link.

You are about to leave travel.state.gov for an external website that is not maintained by the U.S. Department of State.

Links to external websites are provided as a convenience and should not be construed as an endorsement by the U.S. Department of State of the views or products contained therein. If you wish to remain on travel.state.gov, click the "cancel" message.

You are about to visit:

Thai Destination

Update to Covid-19 vaccine guide for travellers to Thailand

The tourism authority of thailand (tat) on monday provided an update to guide to covid-19 vaccines for international travellers to thailand effective from december 16, 2021..

International travellers, including returning Thais and foreign residents, who are above 18 years of age should get fully vaccinated for Covid-19 with a vaccine approved by Thailand’s Ministry of Public Health (MoPH) or the World Health Organisation (WHO) no less than 14 days before their travel date.

Travellers 12-17 years of age, travelling with parents under the Test & Go entry scheme and Sandbox Programme, are not required to be vaccinated but must have a negative RT-PCR test result within 72 hours before travelling. Those unaccompanied must get vaccinated with at least one dose of an approved vaccine and must have a negative RT-PCR test result.

Travellers 6-11 years of age, travelling with parents under the Test & Go entry scheme and Sandbox Programme, must have a negative RT-PCR test result within 72 hours before travelling.

Travellers under 6 years of age, travelling with parents with a negative RT-PCR test result within 72 hours before travelling, are not required to have a pre-arrival negative RT-PCR test result and can have saliva test when entering the Kingdom.

Travellers previously infected within 3 months before travelling must have a medical certificate of recovery or get vaccinated with at least one dose of an approved vaccine for an unspecified period of time before travelling.

List of approved Covid-19 vaccines

Currently, the MoPH has approved the following manufacturers and vaccines:

• CoronaVac by Sinovac Biotech Ltd – 2 doses needed / 2-4-week interval;
• AstraZeneca or Covishield by AstraZeneca and the University of Oxford, SK Bioscience (South Korea), Siam Bioscience, and Serum Institute of India (Covishield) – 2 doses needed / 4-12-week interval;
• Pfizer–BioNTech or Comirnaty by Pfizer Inc. and BioNTech 2 doses needed / 3-week interval;
• Janssen or Janssen/Ad26.COV2.S by Johnson & Johnson Services, Inc. – 1 dose needed;
• Moderna by Moderna Inc. – 2 doses needed / 4-week interval);
• Sinopharm or COVILO by Sinopharm Co., Ltd. – 2 doses needed / 3-4-week interval);
• Sputnik V by the Gamaleya Research Institute of Epidemiology and Microbiology – 2 doses needed – 3-week interval).

Meanwhile, the WHO’s guidance on the Covid-19 vaccines is available  here .

Have you been fully vaccinated?

According to the MoPH, travellers are considered fully vaccinated if:

• They get their second dose of a 2-dose vaccine; such as, the AstraZeneca or Pfizer vaccines, no less than 14 days before their travel date to Thailand.
• They get a single-dose vaccine; such as, Janssen vaccine, no less than 14 days before their travel date to Thailand.
• In case of mix-and-match vaccines, travellers should get their second dose of a different vaccine within the recommended interval of the first vaccine no less than 14 days before their travel date to Thailand. For example, if the first vaccine is CoronaVac from Sinovac Biotech and the second vaccine is AstraZeneca, the time between the two doses is 2-4 weeks.

Travellers who do not meet these criteria may be denied entry into Thailand.

Requirements for the ‘Certificate of Covid-19 Vaccination’

The travellers’ Certificate of Covid-19 Vaccination should contain the following details:

• Given name and last name;
• Date of Birth;  
• Nationality;
• Passport or Identification No.;
• Name of the Covid-19 vaccine;
• Vaccination dates;
• Vaccine manufacturer and lot/batch number;
• Authorised organisation in the country of origin.

In addition to being fully vaccinated, international travellers should have all of their advance arrangements in good order for arrival and entry. For more information on Thailand’s reopening programmes, see:  https://www.tatnews.org/thailand-reopening/ .

MOST VIEWED

Thailand launches anti-dumping probe on chinese extruded aluminium, credit bureau rings alarm bells on debt-ridden smes failing, pita heads to harvard as a visiting democracy fellow, mpox strain in patient not confirmed yet: thai disease control chief, china’s tourism more than just great wall and panda, 3-day event in bangkok shows.

Cookies on GOV.UK

We use some essential cookies to make this website work.

We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.

We also use cookies set by other sites to help us deliver content from their services.

You have accepted additional cookies. You can change your cookie settings at any time.

You have rejected additional cookies. You can change your cookie settings at any time.

• Passports, travel and living abroad
• Travel abroad
• Foreign travel advice

Before you travel check that:

• your destination can provide the healthcare you may need
• you have  appropriate travel insurance  for local treatment or unexpected medical evacuation

This is particularly important if you have a health condition or are pregnant.

Emergency medical number

Dial 191 and ask for an ambulance.

Local number: 1669

Contact your insurance or medical assistance company quickly if you’re referred to a medical facility for treatment.

Vaccine recommendations and health risks

At least 8 weeks before your trip:

• check the latest information on vaccinations and health risks in  TravelHealthPro’s Thailand guide
• see where to get vaccines and whether you have to pay on the  NHS travel vaccinations page

See what health risks you’ll face in Thailand , including: 

• malaria and dengue

Altitude sickness is a risk in parts of Thailand. Read more about altitude sickness on TravelHealthPro . 

Air quality

There can be high levels of air pollution in large cities. This includes Bangkok and Chiang Mai, which are also affected by seasonal regional smoke haze caused by farmers burning trees and crops. The high pollution and  particulate count  sometimes reach dangerous levels. This may worsen bronchial, sinus or asthma conditions.

Check air quality levels for many cities on the  World Air Quality Index website .

The legal status and regulation of some medicines prescribed or bought in the UK can be different in other countries.

Hospitals and pharmacies across Thailand will usually accept UK prescriptions. Brand-name medication can often be more expensive than locally produced medication.

Medication sold on the street may not be genuine or may have been stolen. Taking medication without medical advice or a prescription can have serious health consequences.

Read  best practice when travelling with medicines on TravelHealthPro .

Healthcare in Thailand

FCDO has a list of  medical facilities in Thailand where some staff will speak English.

All hospitals require a guarantee of payment before treating patients. Make sure you have adequate health insurance.

Private hospitals in Thailand are of a high standard but can be expensive. Public hospitals and clinics do not always meet UK standards, particularly outside Bangkok.

Travel and mental health

Read  FCDO guidance on travel and mental health . There is also  mental health guidance on TravelHealthPro .

Related content

Is this page useful.

• Yes this page is useful
• No this page is not useful

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.

To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab) .

Why is mpox an emergency again, and how worried should I be?

• Medium Text

WHAT IS MPOX?

What is a global health emergency, why is mpox an emergency again.

WHAT HAPPENS NOW?

How worried should i be.

Sign up here.

Reporting by Jennifer Rigby; Editing by Crispian Balmer and Jan Harvey

Our Standards: The Thomson Reuters Trust Principles. , opens new tab

Thomson Reuters

Jen reports on health issues affecting people around the world, from malaria to malnutrition. Part of the Health & Pharma team, recent notable pieces include an investigation into healthcare for young transgender people in the UK as well as stories on the rise in measles after COVID hit routine vaccination, as well as efforts to prevent the next pandemic. She previously worked at the Telegraph newspaper and Channel 4 News in the UK, as well as freelance in Myanmar and the Czech Republic.

Chipmaker Analog Devices forecasts strong Q4 results as demand recovers

Analog Devices forecast fourth-quarter revenue and profit above Wall Street expectations on Wednesday, as it benefits from returning demand for its chips used in consumer electronics.

An official website of the United States government

Here’s how you know

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Government’s Response to the Clade I Mpox Outbreak in the Democratic Republic of the Congo and Other Countries in the Region

This week, the Africa Centres for Disease Control and Prevention (Africa CDC) declared the mpox clade I outbreak a Public Health Emergency of Continental Security, and the World Health Organization (WHO) declared this outbreak a Public Health Emergency of International Concern. The United States government supports those declarations. The United States will continue to work closely with African governments, Africa CDC and WHO to ensure an effective response to the current outbreak and to protect the health and lives of people of the region.

In 2022, the world experienced a global outbreak of clade II mpox, which led to more than 95,000 cases across 115 non-endemic countries. Clade I mpox tends to cause a higher number of severe infections and have a higher mortality rate than clade II mpox. The evidence for clade I mpox clinical outcomes is based primarily on data from endemic countries, particularly DRC. We expect it would cause lower morbidity and mortality in the United States than in the DRC.

DRC is currently experiencing the largest number of annual suspect cases ever recorded and the disease has now been identified in several neighboring countries where mpox (clade I or clade II) has not been found in the past.

U.S. Government Partnership on the Mpox Response

The United States Government has been closely monitoring the spread of clade I mpox in the DRC and neighboring countries since 2023, and we have been working closely with the Government of DRC, as well as regional and global health partners to reduce the impact of this outbreak and safeguard public health. U.S. government support for the mpox response also builds on our robust, longstanding health partnerships with DRC and throughout Africa, which have helped combat infectious diseases such as HIV, tuberculosis, and malaria for over 20 years. In fiscal year 2023, the United States allocated more than $2.65 billion in bilateral health funding in Central and Eastern Africa. This response also builds on a longstanding partnership on global health security between DRC and the United States.

In addition to ongoing health support, in the last few months the United States has provided an additional $17 million USD to support clade I mpox preparedness and response efforts in Central and Eastern Africa. The funding has enabled stronger surveillance, risk communication, and community engagement, as well as needed laboratory supplies and diagnostics, clinical services, and vaccine planning.

Vaccination will be a critical element of the response to this outbreak. To support this effort, the United States is donating 50,000 doses of the Food and Drug Administration (FDA)-approved JYNNEOS vaccine to DRC. The United States is working with other countries, WHO, and international partners to encourage donations that support vaccine efforts and address challenges to vaccine delivery.

Mpox Preparedness for the United States

The risk to the general public in the United States from clade I mpox circulating in the DRC is very low, and there are no known cases in the United States at this time. Due to efforts over the last nine months, the United States is well prepared to rapidly detect, contain, and manage clade I cases should they be identified domestically. The United States has a robust surveillance system in place, including through clinical testing and wastewater analysis. We continue to encourage those at high risk to get vaccinated with the JYNNEOS mpox vaccine, which has been demonstrated to be safe and highly effective at preventing severe disease from mpox. Those who have already had clade II mpox or are fully vaccinated against mpox are expected to be protected against severe illness from clade I mpox.

CDC has issued an updated Health Alert Network advisory urging clinicians to consider clade I mpox in people who have been in DRC or neighboring countries in the previous 21 days; clinicians are also asked to submit specimens for clade-specific testing for these patients if they have symptoms consistent with mpox. Given the geographic spread of clade I mpox, the U.S. CDC issued an updated Travel Health Notice on Aug. 7, 2024, recommending travelers to DRC and neighboring countries practice enhanced precautions.

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Subscribe to RSS

Receive latest updates

Related News Releases

Hhs participates in annual u.s.-japan health security committee meeting, readout of hhs secretary xavier becerra’s meeting with minister keizo takemi, ministry of health, labour, and welfare of japan and minister mark holland, canada minister of health., statement from secretary xavier becerra on amended international health regulations, related blog posts.

Tools to Help Us Work Together to Eliminate Viral Hepatitis in the U.S.

Giving blood saves lives.

U.S. Summary of the 75th World Health Assembly

Media inquiries.

For general media inquiries, please contact  [email protected] .

Disclaimer Policy: Links with this icon ( ) mean that you are leaving the HHS website.

• The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
• Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
• You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
• HHS is not responsible for Section 508 compliance (accessibility) on private websites.

For more information on HHS's web notification policies, see Website Disclaimers .

Mpox, Explained: Key Details On Latest Virus Outbreak

• Share to Facebook
• Share to Twitter
• Share to Linkedin

Officials in Thailand on Wednesday said they have detected a new case of mpox in the country and are investigating to see whether the variant is the same linked to a growing outbreak in central Africa.

A WHO official said mpox is not the new COVID.

August 21 Thailand detected an mpox case in a European tourist arriving from Africa last week and health officials said they are treating it as if it is the newer clade I form of mpox while awaiting test results to ascertain the strain, with the results expected in a few days.

August 20 Mpox is not the new COVID, WHO regional director for Europe Hans Kluge told reporters, urging nations to collaborate in order to “control and eliminate mpox globally” with well-known strategies rather than “enter another cycle of panic and neglect.”

August 19 The Philippines reported its first case of mpox this year in a 33-year-old man with no history of travel outside the country, the Department of Health said , later adding that the case is not the same form as the newer clade I variant driving a growing outbreak in Africa but the milder clade 2 variant.

August 16 Pakistan confirmed at least one case of mpox in a patient returning from an unspecified Gulf country—reports have named both Saudi Arabia and the United Arab Emirates (UAE)—though testing later revealed it was not the new clade Ib strain but the distinct clade II variety.

August 15 Sweden became the first country outside of Africa to report an mpox infection caused by the clade I variant, though officials said the person had been infected during a stay in the region and stressed the risk to the general population from the virus is “very low.”

August 16 The World Health Organization declared the mpox outbreak a public health emergency of international concern, the agency’s highest level of alert under international law.

August 13 At least 12 countries in Africa have reported mpox outbreaks so far, the Africa Centers for Disease Control and Prevention (Africa CDC) said when declaring an emergency, including four—Burundi, Kenya, Rwanda and Uganda—that have not reported mpox before.

August 13 The vast majority of cases have been reported in the Democratic Republic of Congo (DRC), the historic confines of the variant for more than a decade, and at least 12 nearby countries , including those listed above, have confirmed cases or are considered to be at high risk due to sharing a border with the DRC: Republic of the Congo, Central African Republic, Rwanda, Cameroon, Gabon, Angola, South Sudan, Tanzania and Zambia.

Crucial Quote

“We encourage all countries to enhance surveillance, share data, and work to better understand the transmission; share tools like vaccines; and apply lessons learned from prior public health emergencies of international concern in addressing the current outbreak,” WHO chief Tedros Adhanom Ghebreyesus said .

How Many Cases Have Been Reported?

African officials have confirmed 2,863 mpox cases and 517 deaths in 2024 so far, according to Africa CDC, most in the DRC. Only a fraction of suspected infections are genetically tested to confirm mpox and determine the variant responsible and officials said the number of suspected cases have already surpassed 17,000, vastly exceeding last year’s total around 15,600 cases and 537 deaths. These figures are “just the tip of the iceberg, experts said, due to difficulties with tracking and testing cases.

What Is Mpox?

Mpox, formerly known as monkeypox, is a viral illness caused by infection with the monkeypox virus. The virus belongs to a large family of viruses known to cause disease in humans and other animals, including smallpox, or variola, cowpox, Alaskapox , and vaccinia, a weakened form of which is used in mpox and smallpox vaccines. Mpox infections are typically mild but infections can and do kill, with data suggesting the clade I variant has a death rate as high as 10%. Young children, pregnant people and those with compromised immune systems are most at risk of poor outcomes. Symptoms of infection include a fever, swollen lymph nodes and characteristic, pus-filled rash and the virus spreads primarily through close contact with infected people, animals or contaminated materials like towels.

Are There Mpox Vaccines?

Yes. The preferred choice among health officials is Bavarian Nordic’s two-dose vaccine. The shot, sold as Jynneos, Imvamune and Imvanex, has a more favorable risk profile to available alternatives and has been authorized for use against mpox by major health agencies around the world, including the Food and Drug Administration. The company says it can supply 10 million shots to combat the outbreak by the end of 2025, with 2 million by the end of the year. There are plentiful stores of Emergent BioSolutions’ smallpox vaccine ACAM2000 in national stockpiles around the world. The shot, kept for national security in case the now-eradicated smallpox somehow resurfaces or is deployed as a weapon, is not generally favored for widespread use due to its higher risk of potentially serious side effects but could be turned to protect against mpox if needed. KM Biologics secured approval for its smallpox and mpox vaccine, LC16, in its home country of Japan during the 2022 outbreak. But the company has not sought widespread approval for the shot around the world and it is not commercially available. There are reportedly significant supplies in Japan’s national stockpile should Tokyo release them. Another smallpox vaccine that could be turned against mpox has also been approved in Russia. The shot, which the WHO says is the “first fourth-generation smallpox/orthopoxvirus vaccine,” is not widely available, however, and given the agency that developed it, it is not known whether Moscow would share supplies internationally. The shot was developed and registered by Russia’s Vector institute, the historic home of the Soviet Union’s biological weapons program and host to one of two authorized smallpox repositories globally (the other being the CDC).

Who Should Get Vaccinated Against Mpox?

Most countries consider the risk of an mpox outbreak to be very low and have not endorsed widespread vaccination. The Centers for Disease Control and Prevention recommends mpox vaccination in the U.S. for the at-risk groups identified during the last global outbreak in 2022 and while cases have fallen, the virus variant still circulates. This includes gay, bisexual or other men who have sex with men or transgender, nonbinary or gender-diverse people, particularly those who have multiple sex partners, have sex at commercial sex venues like clubs or saunas and have received a new diagnosis of a sexually transmitted infection like chlamydia, gonorrhea or syphilis in the last six months. People with an occupational risk of exposure such as laboratory or healthcare workers are also recommended to get the shot, as are people who have had sex with or been exposed to someone diagnosed with mpox. The agency recommends two doses of Jynneos administered four weeks apart.

What Happened To The Other Mpox Variant?

The clade II variant that drove the 2022 mpox outbreak is still circulating. Cases in Western countries have dwindled following widespread vaccination efforts but cases still crop up and officials monitor the virus’ movements closely. The variant is also still responsible for outbreaks in Africa, predominantly western Africa, where it has historically circulated. When reporting on the clade I outbreak, the WHO noted a “separate” mpox outbreak in the Côte d’Ivoire linked to clade II.

Further Reading

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here .

• Editorial Standards
• Reprints & Permissions

Join The Conversation

One Community. Many Voices. Create a free account to share your thoughts. 

Forbes Community Guidelines

Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.

In order to do so, please follow the posting rules in our site's  Terms of Service.   We've summarized some of those key rules below. Simply put, keep it civil.

Your post will be rejected if we notice that it seems to contain:

• False or intentionally out-of-context or misleading information
• Insults, profanity, incoherent, obscene or inflammatory language or threats of any kind
• Attacks on the identity of other commenters or the article's author
• Content that otherwise violates our site's  terms.

User accounts will be blocked if we notice or believe that users are engaged in:

• Continuous attempts to re-post comments that have been previously moderated/rejected
• Racist, sexist, homophobic or other discriminatory comments
• Attempts or tactics that put the site security at risk
• Actions that otherwise violate our site's  terms.

So, how can you be a power user?

• Stay on topic and share your insights
• Feel free to be clear and thoughtful to get your point across
• ‘Like’ or ‘Dislike’ to show your point of view.
• Protect your community.
• Use the report tool to alert us when someone breaks the rules.

Thanks for reading our community guidelines. Please read the full list of posting rules found in our site's  Terms of Service.

WHO declares mpox virus a public health emergency of international concern

Facebook Twitter Print Email

The chief of the World Health Organization (WHO) declared that the rise in mpox cases constitutes a public health emergency of international concern (PHEIC) , following advice from members at Wednesday’s International Health Regulations (IHR) Emergency Committee meeting.      

A PHEIC is the highest level of alarm under international health law. 

The WHO Director-General, Tedros Adhanom Ghebreyesus, called for the meeting last Wednesday to seek advice on whether the mpox – previously monkeypox – outbreaks are cause for international concern. 

On Tuesday, the Africa Centres for Disease Control and Prevention (CDC) declared the situation a public health emergency.

“The Emergency Committee’s advice to me, and that of the [Africa CDC], which yesterday declared a public health emergency of regional security, are aligned,” Tedros said in a post on the social media platform X, formerly Twitter. 

Clades and cases 

Mpox cases have been spreading throughout many countries in Africa, particularly the Democratic Republic of the Congo (DRC) and neighbouring Burundi, Kenya, Rwanda and Uganda. The potential for further spread in Africa is worrying, said the WHO chief. 

“In addition to other outbreaks of other clades of mpox in other parts of Africa, it’s clear that a coordinated international response is essential to stop these outbreaks and save lives,” Tedros said. 

This year already saw over 14,000 reported cases of the virus with 524 deaths, a significant increase in reported cases from 2023. 

Tedros previously mentioned that the mpox outbreaks have occurred due to different viruses called clades.

At Wednesday’s meeting , he said there was transmission of the so-called clade 1b virus in the DRC last year which was caused “mainly through sexual networks”. This clade is reportedly deadlier and more easily transmitted from person to person.

Clade 1 has been circulating in the DRC for years while clade 2 was responsible for the global outbreak of 2022 which was declared an international public health emergency.  

Tedros said in the past month that around 90 cases of successor clade 1b were reported in countries neighbouring the DRC which had not reported mpox cases before. 

“Stopping these outbreaks will require a tailored and comprehensive response, with communities at the centre, as always,” Tedros said. 

Addressing outbreak drivers

The WHO chief said the UN agency is working with governments of the affected countries, the Africa CDC and other partners to “understand and address the drivers of these outbreaks”.

“For example, we are providing machines to analyse blood samples and confirm cases of mpo [and] supporting laboratories to sequence viral samples,” he said.

He further mentioned “supporting case investigation and contact tracing” on the ground, training for health care workers and much more . 

WHO regional response

“WHO has developed a regional response plan, requiring an initial $15 million to support surveillance, preparedness and response activities,” Tedros said.

This response was funded by $1.45 million from the WHO Contingency Fund for Emergencies.

More funds will be released in the coming days and the WHO chief is also appealing for more donor support. 

Emergency vaccines 

Currently, two WHO-recommended and approved vaccines are being used to combat the mpox virus outbreak.

Under an Emergency Use Listing (EUL) call last week , Tedros also invited manufacturers of mpox vaccines to express interest in producing them to “accelerate vaccine access for lower-income countries which have not yet issued their own national regulatory approval”.

EUL will allow partners like the UN Children’s Fund ( UNICEF ) to gather vaccines for distribution.

 “We are working with all partners to facilitate equitable access to diagnostics, vaccines, supplies for clinical care and other tools," Tedros said.

WHO recommendations

Last August, the WHO chief released standing recommendations under the IHR to monitor mpox cases. 

These recommendations were set to expire in five days, on 20 August 2024, but will be extended for another year to “support countries to respond to the chronic risk of mpox".

Some of the recommendations include enhancing community protection through adapting public health and social measures to local contexts, providing guidance and resources for delivering clinical mpox care and more. 

Tedros said WHO is “committed in the days and weeks ahead to coordinate the global response, working closely with each of the affected countries and leveraging our on-the-ground presence t o prevent transmission, treat those infected and save lives ”.